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INTRODUCTION
In 1788, Mr. Cawley reported a young vagabond who
died after losing a lot of weight and suffering from
diabetes, in whom autopsy revealed multiple pancreatic
stones.1 In 1878, Friedrich wrote, “I am sure that
extensive chronic interstitial pancreatitis could be caused
by severe alcoholism (drunkard’s pancreas).” Prior to
1940, chronic pancreatitis is more of a post-autopsy
diagnosis, since it has not been clinically acknowledged.2
In 1946, chronic pancreatitis has become known as a
separate disease entity when Comfort et al emphasized
the presence of a correlation between chronic
pancreatitis and alcoholism, as well as explicated the
patient’s clinical manifestations. They hypothesized that
(chronic – red?) pancreatitis is a result of recurrent
attacks of acute pancreatitis. Studies in the 1960s and
1970s refuted this hypothesis and began to lead to the
concept that chronic pancreatitis is chronic from the
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ABSTRACT
Chronic pancreatitis is still considered an uncertain process with an undetermined pathogenesis and ill
defined treatment. Chronic pancreatitis is distinguished from acute pancreatitis based on structural and
functional differences. In acute pancreatitis, the gland is normal prior to the attack, and returns to normal
after an acute attack, while in chronic pancreatitis, the gland is already in an abnormal state prior to or
following an attack or prior to and following an acute attack.
The most common local complication of chronic pancreatitis is the formation of pseudocysts. Psedocysts
are usually formed due to passage obstruction of the pancreatic tract (retention cyst) or due to recurrent
acute exacerbation
 Several pancreatic abnormalities, such as stones, ductal stricture, fluid collection, and functional sphincter
abnormality, could be treated using endoscopy. Adjuvant treatment for biliary duct abnormality such as
biliary stricture due to pancreatitis, and stent insertion in cases of duodenal obstruction, could also be
performed via endoscopy
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beginning and differs from acute pancreatitis. In 1993,
Kloppel and Maillet suggested a new concept that has
lately gained popularity. They stated that a series of
necrosis-fibrosis occurs, and chronic pancreatitis is a
result of recurrent acute attacks of alcoholic
pancreatitis, both those with clinical as well as
subclinical manifestations
.
1,2
 After two decades since the
initial description, there is a great deal of publications on
this disease, but chronic pancreatitis is still considered
an uncertain process with an undetermined
pathogenesis and ill defined treatment.
Definition and Classification
Chronic pancreatitis is a continuous inflammatory
disease of the pancreas characterized by irreversible
morphological changes and uniquely causes permanent
pain and/or dysfunction.3,4 Chronic pancreatitis is
distinguished from acute pancreatitis based on structural
and functional differences. In acute pancreatitis, the gland
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is normal prior to the attack, and returns to normal after
an acute attack, while in chronic pancreatitis, the gland
is already in an abnormal state prior to or following an
attack or prior to and following an acute attack.1
The morphological changes in chronic pancreatitis
includes edema of varying degrees, inflammation, and
necrosis, based on findings of chronic changes such as
fibrosis, inflammation, and loss of exocrine function. We
could also see elements of ductal widening, intraductal
protein clots, and calcification.5, 6
Epidemiology
In several Western industrialized nations, the
prevalence of chronic pancreatitis is estimated to be 10
to 15 per 100,000 inhabitants, with an annual incidence
rate of 3.5 to 4 per 100,000 inhabitants. This estimation
particularly illustrates alcoholic chronic pancreatitis, and
is thus proportional with alcohol consumption in the
nation in question. Males are more frequently inflicted,
probably portraying the fact that they more commonly
consume alcohol and are thus more susceptible to chronic
pancreatitis. The rate above could very well be
underestimated, noting that diagnosis is often not
established using high tech instruments such as
computed tomography (CT) or ERCP.7
In a study in Japan, the incidence and prevalence of
chronic pancreatitis is higher than that reported in the
West (reports include 12.4 per 100,000 and 45.5 per
100,000 inhabitants). They probably established the
diagnosis based on CT scan, ERCP, or other imaging
modalities. Based on the survey, the prevalence of
chronic pancreatitis in South India is approximately 125
per 100,000 inhabitants.7 Most of them consist of
tropical pancreatitis, characterized by pancreatic
calcification. Community-based data from other areas
and nations is still much required.
Etiopathogenesis
In most nations, the most common cause of chronic
pancreatitis is alcoholism, ranging from 60 to 70% of all
chronic pancreatitis.2, 4, 6, 8 In certain countries such as
India, the majority of patients with chronic pancreatitis
suffer from tropical pancreatitis. Other forms of
pancreatitis are hereditary pancreatitis, obstructional
pancreatitis, autoimmune pancreatitis, and
hyperparathyroid associated pancreatitis.2 It is still in
argument whether pancreatitis divisum could cause
chronic pancreatitis. Pancreatitis of unknown origin is
classified as idiopathic pancreatitis.6
Alcoholism
The correlation between chronic pancreatitis and
long-term alcohol consumption has long been established.
In patients with alcoholic pancreatitis, the amount of
consumed alcohol vary from 150 to 175 grams per day,
with a mean alcohol consumption of 18 ± 11 years for
males and 11 ± 8 years among females. The risk for
pancreatitis increases proportionally with the daily
intake of alcohol.2, 7, 8
It is unclear whether alcohol is a direct toxin or causes
pancreatitis by indirect means. Alcohol is metabolized in
the pancreas, stimulating destruction of lysozomes and
increasing triglyceride content in acinar cells. There are
many hypotheses that have been presented to explain
the pathogenesis, such as the “Toxic-metabolic”
hypothesis, obstruction due to protein hypersecretion, “
necrosis-fibrosis” and “oxidative stress” hypotheses. Out
of all of these theories, only the “necrosis-fibrosis” and
“obstruction” hypotheses are commonly used by
researchers.4, 7
Sarles and Sahel preferred the obstruction
hypothesis, and also emphasizes that alcoholic
pancreatitis is chronic in progression from the onset of
the disease. According to this theory, alcohol stimulates
increased protein content in pancreatic juice, which
results in formation of protein plaques in small
pancreatic ducts. Protein plaques cause ductal
obstruction and eventual calcification. Ductal
obstruction causes atrophy of acinar atrophy periductal
inflammation, and eventual pancreatic fibrosis. Under
normal conditions, pancreatic secretory protein (PSP)
or lithostatin prevents precipitation of calcium
carbonate, and is believed to play an important role in
the etiopathogenesis process.4,6,7 Reduced lithostatin
protein secretion facilitates protein plaque calcification.
This occurs during the initial development of the disease,
where there is imbalance between stone formation
promoter and inhibitor. Several points that cannot be
explained by the theory is: (1) most patients with
alcoholic pancreatitis come with acute pancreatitis, (2)
50% of patients who die from alcoholic pancreatitis do
not demonstrate chronic histophatological changes from
their autopsy, (3) many patients with chronic pancreatits
demonstrate autodigestive necrosis in their pancreas, and
(4) changes in lithostatin secretion is not always found.7
The necrosis-fibrosis hypothesis is based on the
concept of recurrent acute alcoholic pancreatitis that
causes recurrent pancreatic damage. The supporters of
this hypothesis believe that peri-acinar and periductal fatty
necrosis stimulates periductal fibrosis and then causes
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ductal stasis and eventual protein plaque and stone
formation. Total ductal obstruction would result in
acinar cell necrosis, inflammation, and fibrosis.
Resorption of the necrotic area, such as in hemorrhagic
necrosis in the pancreas, results in perilobular necrosis
mediated by various mediators such as the transforming
growth factor (beta-TGF).
It has been demonstrated that alcoholic pancreatitis
can be classified into progressive and non-progressive
alcoholic pancreatits.6 If patients do not suffer from
severe pancreatitis at the initial attack, their risk for
chronic pancreatitis is less compared to patients who
suffer from severe pancreatitis at the initial development
of the disease. For this reason, Amman and Muellhaupt
demonstrated that the progression of alcoholic
pancreatitis is correlated with the severity of acute
attack. Patients who suffer from recurrent and severe
pancreatitis with pseudocyst formation more easily
develop calcification pancreatitis. Unfortunately, this
hypothesis is unable to explain the following
phenomena: (1) how alcohol causes acinar dysfunction
and necrosis, (2) how primary chronic pancreatitis
occurs in 5-10% of alcoholics, and (3) why biliary
pancreatitis never become chronic pancreatitis, even
though patients with biliary pancreatitis suffer from
recurrent acute pancreatitis.7, 9
GENETIC MUTATION
The discovery of genetic mutation on the long arm of
chromosome 7, which codes cationic trypsinogen in
patients with hereditary pancreatitis, clarifies the old belief
that there is a genetic defect in patients with hereditary
pancreatitis. R122H mutation (mutation of histidine into
arginine on codon 122, axon 3) eliminates the region that
has the capacity to hydrolyze the trypsin chain that
connects two half chains of trypsin. As a result, the
trypsin is not activated due to a missing hydrolyzing part.
Another mutation in codon 29 (N29I, axon 2) has also
been discovered in a Japanese family with hereditary
pancreatitis.7, 10, 11
Autoimmune Pancreatitis
A specific type of pancreatitis has been identified in
Japan. Mr. Ito et al explained 3 cases of autoimmune
pancreatitis with diffuse narrowing and irregularity of
the main pancreatic duct. All patients improved with
corticosteroid administration. Autoantibodies, particularly
anti-nuclear and anti-carbonic anhydration, are commonly
found in patients with autoimmune pancreatitis.4, 7
Tropical Pancreatitis
The chief hypothesis in tropical pancreatitis is that it
is due to the consumption of a cassava-type plant
containing cyanogenic glycoside, which is freely
consumed by inhabitants of South India. Nevertheless,
the hypothesis is not commonly accepted because: (1)
the plant is not always consumed by many patients with
tropical pancreatitis, (2) there is no difference in con-
sumption of the plant by patients with pancreatitis and
those without, and (3) long-term consumption of the plant
does not cause diabetes or pancreatitis in rats.4, 7, 12
Table 1. The Difference Between Alcoholic and 
Tropical Pancreatitis 
Clinical findings Alcoholic Tropical 
Age (years) 30-40 10-30 
Pain (%) 85-90 0-80 
Calcification moderate dominant 
Steatorrhea common rare 
Diabetes (%) 30-70 80 
Insulin requirement (units) 10-40 60-200 
Cancer (%) 3-4 9.2 
Quoted from 12 
Malnutrition with protein and micronutrient deficiency
has also been considered a cause of tropical
pancreatitis, as malnutrition could cause pancreatic
atrophy. However, malnutrition does not always cause
pancreatitis, but is instead a more common consequence
of pancreatitis.
The pathogenesis of tropical pancreatitis is not well
known. Histopathological changes include extensive
acinar destruction, fibrosis, and ductal dilatation.
Immune response disorder, suspicion of infection, and
genetic susceptibility are factors that play a role in the
etiopathogenesis of tropical pancreatitis.
Progression of The Disease and Differential
Diagnosis
Chronic pancreatitis is always marked by
progressive and continuous loss of pancreatic tissue.1
Following the subclinical phase, which varies in time span,
the patient would develop recurrent abdominal pain
accompanied by exocrine and endocrine deficiency. In
most cases, both exocrine and endocrine function will
be reduced, even though reduced endocrine function
usually occurs more slowly. Several researchers state
that progressive loss of pancreatic function causes
reduced or absence of pain, while other researchers did
not find the phenomena, thus creating a continuous
controversy. The impact of cessation of alcohol
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consumption on the progression of pancreatitis is also
unclear. Several reports state that cessation of alcohol
consumption reduces the frequency and severity of pain
and the rate of exocrine and endocrine loss. On the other
hand, other researchers state that progression will
continue despite cessation or continuation of alcohol
consumption.
Chronic pancreatitis is associated with a mortality rate
of nearly 50% in 20 to 25 years. Approximately 15 to
20% of patients die due to complication of acute attacks.
Recent report indicate that pancreatic cancer develops
at a rate of approximately 4% after the diagnosis is es-
tablished.1
The most common local complication of chronic
pancreatitis is the formation of pseudocysts. Psedocysts
are usually formed due to passage obstruction of the
pancreatic tract (retention cyst) or due to recurrent acute
exacerbation. Another complication is stricture of the
biliary tract, which could occur in 3.2% to 45.6% of cases
of chronic pancreatitis. Splenic vein thrombosis occurs
in almost 10% of cases, which of course could cause
varices of the gastric fundus. A rare complication is
pancreatic ascites due to pancreatic juice diffusing into
the peritoneal cavity from a ruptured duct or pseudocyst.
Other complications include pancreaticopleural fistula,
obstruction of the biliary duct, and duodenal obstruction.6
Malabsorption of vitamin B12 occurs in 40% of
patients with chronic alcoholic pancreatitis and almost
all patients with cystic fibrosis. Such malabsorption
occurs since vitamin B12 is bound to its binding protein
in excessive amounts, while under normal conditions, B12
is more commonly bound to intrinsic factors. Almost all
patients suffer from glucose intolerance, but few up to
the point of diabetic ketoacidosis and complications of
peripheral organs (retinopathy, neuropathy, or
nephropathy).6
A differential diagnosis of chronic pancreatitis
occurs when we are dealing with two conditions. Firstly,
in patients with abdominal pain and normal or minimal
imaging findings, pancreatic function may be useful. The
second challenge is in patients with suspicion of chronic
pancreatitis, which is actually pancreatic cancer. Under
such condition, establishing the diagnosis of pancreatic
cancer is quite difficult. ERCP plus brush cytology may
be useful in such condition. Stricture of the pancreatic
tract of over 1 cm unaccompanied by enlarged branches
creates the suspicion of pancreatic cancer. The
sensitivity of brush cytology is only 20-25%, and the
specificity is nearly 100%. Another diagnostic
procedure for suspected pancreatic cancer is
pancreatic juice cytology, FNAB, and of course
assessments of CA 19-9 and CEA tumor markers.1, 13
CLINICAL PRESENTATION
Clinical History and Physical Examination
Four cardinal manifestations of chronic pancreatitis
are prolonged or recurrent abdominal pain 1, diabetes 7,
steatorrhea 5, and calcification.6  Abdominal pain is
usually what brings the patient to the doctor in the first
instance.2
In developed nations, most patients have a history of
severe and long standing alcoholism. They usually
report recurrent attacks of upper abdominal pain, often
spreading into the mid back or scapula, increasing after
meals and lessening when leaning frontward and sitting
up. The pain is usually accompanied by nausea and
vomiting. It may be continuous or intermittent, and is not
relieved with antacids. The pain aggravates with alcohol
or fat. In chronic pancreatitis, the pain often requires the
use of narcotic pain relief. Ten to 20% of patients
manifest with painless pancreatitis. Old-age onset chronic
pancreatitis and tropical pancreatitis accompanied by
diabetes are often painless in nature.
Patients could present with diabetes, jaundice, or
malabsorption. Steaotorrhea with weight loss and
diabetes usually reflect advanced disease. Exocrine and
endocrine tissue is estimated to have been reduced
80-90% prior to the development of malabsorption and
diabetes. Deficiency of fat-soluble vitamins is rarely
found.
Physical examination usually does not reveal a lot of
abnormality, and there is often a discrepancy between
abdominal pain and physical findings. Sometimes there
is epigastric tenderness. Subfebrile fever or epigastric
mass reflect complication, in the form of pseudocyt
formation. 6
Laboratory Assessment
Serum amylase or lipase is usually normal or mildly
elevated, particularly if there is extensive fibrosis and the
pancreas is no longer able to synthesize adequate amounts
of enzyme. Leukocyte count and electrolytes are also
usually normal, except if there is vomiting or inadequate
food intake. If alcoholic liver disease is found, liver
function test results are usually abnormal. In as many as 5
to 10% of patients with chronic pancreatitis, edema or
fibrosis associated compression of the intrapancreatic
segment of the biliary duct results in increased serum
bilirubin and base phosphatase. Malabsorption due to
exocrine insufficiency results in increased stool fat. Such
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condition can be detected using Sudan staining and
quantitative assessment for stool fat excretion following a
diet containing 100 g of fat per day. Stool pancreatic
chymotrypsin and elastase testing is usually beneficial to
confirm advanced chronic pancreatitis. Serum elastase,
deoxyribonuclease, and rybonuclease are increased along
with trypsin or creatinine clearance ratio.
Many patients demonstrate glucose intolerance, some
demonstrating increased fasting blood glucose.
PANCREATIC FUNCTION TEST
Pancreatic function is particularly helpful to assist the
diagnosis and treatment of patients with recurrent
abdominal pain whose imaging are within normal limits.
A common problem with pancreatic function test is its
insensitivity, particularly during the initial stages of the
disease, so that a negative pancreatic function test    result
does not eliminate the possibility of chronic pancreatitis.
The test performed obviously depend on the expertise
and available resources.1, 6
A standard pancreatic function test is the collection
of duodenal juices and measurement of its volume,
bicarbonate, and trypsin concentration following secre-
tin injection with pancreozimine or without pancreozimine
(secretin stimulation test). The secretin stimulation test
results are considered to be abnormal if 60% or more
exocrine function has been lost.
Another pancreatic function test consists of substrate
administration to pancreatic enzyme, followed by
measurement of the digestive products of the adminis-
tered substrate. This last test is often called the tubeless
test, since it usually does not use intubation procedures
used in other tests. The problem with this test is it is not
adequately sensitive and specific. Two tests that are
commonly used from the group of tubeless tests are the
bentiromide test and pancreolauryl test. Another test can
be used to diagnose chornic pancreatitis is measurement
of stool chemotrypsin activity and measurement of
serum trypsin-like immonoreactivity.
The sensitivity of pancreatic function tests in
assisting the establishment of the diagnosis is 67-88%,
and the specificity approaches 90% compared to
histological examinations.7
Imaging
In the appropriate clinical setting, the finding of
pancreatic calcification is adequate for the establishment
of a diagnosis. Calcification is found in 30% of cases,
and is a patognomonic sign. Calcification is usually found
in the ductal system and not in the parenchyma. Ultra-
sound examination could demonstrate pancreatic
enlargement, ductal dilatation, or pseudocysts, and has a
sensitivity of 60 to 70% and a specificity of 80 to 90%.
CT has been reported to have a sensitivity of 74 to 90%
and a specificity of 85%. CT could demonstrate
calcification and cyst that could not be demonstrated
using ultrasound. ERCP is a standard imaging proce-
dure used for diagnosis or treatment. Ductal changes
that lead to the suspicion of chronic pancreatitis could
be well      visualized using ERCP. Unfortunately, early
changes are often missed by ERCP. In general, ERCP
has a sensitivity of 66 to 89% compared to histology, and
a specificity of 89 to 100% in advanced pancreatitis.
MRCP is an MRI technique, which is very good in visu-
alizing the pancreatic ductal system and the biliary ducts.
MRCP could provide non-invasive, detailed, 3-dimen-
sional coronal and frontal slices of the pancreatic ducts
and biliary tract. The disadvantage is that it is only able
to demonstrate early ductal changes in 10-25% of cases.5,
1 4
Endoscopic ultrasound is also beneficial to diagnose
chronic pancreatitis, particularly in early stages. A
comparison study revealed that normal endoscopic ul-
trasound findings are correlated with abnormal
pancreatic function test in 87 to 100% of cases. In cases
of early chronic pancreatitis established by endoscopic
ultrasound, pancreatic function test demonstrates
abnormal findings in only 13 to 57% of cases.
Comparison between endoscopic ultrasound and
histology demonstrates a sensitivity of 85% and a
specificity of 67%. Endoscopic ultrasound is able to
demonstrate changes in the ducts and parenchyma, such
as echotexture of the glands, calcification, lobulation, and
fibrotic stranding.3, 7
Based on all of the information above, it could be
noted that if possible (be it rare) to obtain a
histopathological sample, pathological examination is the
best evidence and could be considered to be the gold
standard diagnostic method for chronic pancreatitis.
CT-scan is very good in demonstrating calcification, even
though calcification is usually only found in advanced
stages. ERCP is better in demonstrating ductal changes.
If none of the above examinations are found, pancreatic
function test can be performed. Secretin stimulation test
is the most sensitive examination to determine exocrine
function. An abnormal finding indicates chronic
pancreatitis under the appropriate clinical condition.
Endoscopic ultrasound is beneficial to assist the
establishment of early abnormalities. More data is
needed prior to accepting endoscopic ultrasound as a
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routine examination standard in chronic pancreatitis. The
Asia Pacific Consensus mentions that one positive test
result from the following is adequate for the diagnosis of
chronic pancreatitis: (1) ductal changes under ERCP, (2)
positive secretin stimulation test, (3) pancreatic
calcification found on diagnostic imaging, (4) the
presence of abnormality on endoscopic ultrasound.3, 7, 15
MANAGEMENT
Pain
Pain, both continuous and episodic, is the most
common symptom that brings patients to seek treatment.
Pain is also the most difficult problem to solve. The
pathogeneses of pain that are often mentioned in
references are ductal hypertension, parenchymal
ischemia, perineural eosinophillic inflammation, and
pseudocyst with increased intra-cyst pressure.
Non-invasive approaches include cessation of
alcohol consumption and provoking foods,
administration of non-opioid as well as opioid analgesics,
nerve blocks, cessation of smoking, reduction of
pancreatic secretion using high protease pancreatic
enzyme, cholecystokinin receptor antagonist, or
somatostatin.1 5, 7
Even though proof of efficacy of pancreatic enzyme
is still limited to two random clinical trials, due to its
widespread use, easy administration, and rare side
effects, administration of enzymes is often the first choice
for pain management. In a placebo-controlled,
double-blind crossover study, pancrelipase (Viocase),
with a dose of 6 tablets consumed 4 times a day for 1
month, significantly reduced pain in 75% of patients with
mild to moderate illness. In a multicenter pilot study,
ocreotide, with a subcutaneous dose of 4 x 200
micrograms, reduces the pain score for over 25 in 65%
of patients with severe chronic pancreatitis.1, 5
For patients with continuous pain who have received
maximum non-invasive treatment, ERCP may be
beneficial to re-evaluate the caliber and morphology of
the pancreatic duct. Usually, over half of the patients
who are studied demonstrate ductal dilatation with
several stricture areas, and the remainders have normal
(2-4 mm) ducts and smaller ducts. Ducts larger than 8
mm in diameter could undergo decompression using
internal surgical drainage procedure such as longitudinal
pancreaticojejunostomy (modification of the Peustow
procedure). Ducts less than 8 mm could not undergo
such procedure. Advanced chronic pancreatitis pain
(in large ducts) could be reduced using
pancreaticojejunostomy in 80 to 90% of cases, but 5 years
following surgery, only 50 to 60% of patients are still
free from pain.3, 15
Surgical intervention is usually taken when the pain
continues after other management means, and if (1) there
is temporary ductal dilatation that failed to respond to
endoscopic treatment, (2) there is suspicion of mass of
the pancreatic head, or (3) there are complications such
as pseudocysts, which preclude endoscopic treatment.3,15
Another alternative for drainage is the insertion of an
endoprothesis or stent, placed in the pancreatic duct   using
endoscopy. Recent reports demonstrate that 30 to 76%
patients that undergo stent insertion demonstrate
alleviation of pain symptoms in a follow-up period of 14
to 36 months. Some recommend for stent to be used for
short-term as well as to be used to determine the
possible benefits of surgical intervention.
Patients with pain without pancreatic duct dilatation
are more difficult to manage, since for them surgical
intervention is not possible. Experience using stent in such
conditions is still very limited, but clinical improvement is
reported in 50% of patients. Most patients with pain
without ductal dilatation continue non-invasive treatment
or are recommended for resection. There have been
attempts to percutaneously block the celiac plexus nerves,
but results are still disappointing.
Other treatments that are still under trial and seem to
be promising are: steroid block of the celiac ganglion,
cholecystokinin receptor antagonists, pancreatic stone
dissolving agents, anti-oxidants, and anti-cholinergics.
Malabsorption
If over 90% of exocrine function has been lost,
malabsorption will be clinically manifest. Steatorrhea (fat
malabsorption) causes more of a problem compared to
azotorrhea (protein malabsorption), since it is always
accompanied by diarrhea and gassiness. Treatment
consists of a low fat diet. Patients are usually advised to
eat a diet of approximately 30% fat, 24% protein, and
40% carbohydrate. Moderately long chain triglyceride
is also beneficial, since its absorption require only little
pancreatic enzyme and does not require bile salts. For
continuous complaints, substitution of pancreatic enzyme
should always be administered prior to meals. To avoid
degradation of pancreatic enzymes when passing through
the gaster, the following strategies could be undertaken:
neutralization of gastric acid, prevention of acid
secretion, or using enteric-coated enzymes. There are
no extra benefits of using enzyme agents with high-
lipase action.6, 7
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The Role of Endoscopy
The use of endoscopy for chronic pancreatitis was
first reported in 1997, when pancreatic sphincterotomy
was performed to reduce pain due to stone in the
pancreatic duct. Since then, pancreatic endoscopy has
become more important and is a treatment alternative
for inoperable chronic pancreatitis. In general, the aim
of endoscopic treatment is to alleviate pain.
Several other pancreatic abnormalities, such as
stones, ductal stricture, fluid collection, and functional
sphincter abnormality, could be treated using endoscopy.
Adjuvant treatment for biliary duct abnormality such as
biliary stricture due to pancreatitis, and stent insertion in
cases of duodenal obstruction, could also be performed
via endoscopy. Procedures such as stent insertion or stone
extraction ensure pancreatic drainage and reduce
intraductal pressure. Extra-corporeal shock wave
lithotripsy (ESWL) usually accompanies endoscopy in
cases of large stones.
Complete elimination of the stone from the main
pancreatic duct using endoscopic sphincterotomy and
Dormia net have been achieved in 82% of cases. In
cases of chronic pancreatitis with stricture of the main
pancreatic duct, stent insertion improves clinical
conditions in 70 to 80% of cases.15
CONCLUSION
1. Patients with recurrent, and often unspecific,
abdominal pain, should always warrant the
possibility of chronic pancreatitis.
2. The etiology, pathogenesis, and management of
chronic pancreatitis are still not completely clear.
3. The diagnosis of chronic pancreatitis often requires
complex procedures or instruments.
4. The management of pain in chronic pancreatitis
requires an interdisciplinary approach.
REFERENCES
1. Steer ML, Waxman I, Freedman S. Chronic Pancreatitis. NEMJ
1995; 332: 1482-90.
2. Pitchumoni CS. Pathogenesis of Alcohol-induced Chronic
Pancreatitis. Surgical Clinic of North America April 2001; 81:
379-90.
3. Cooperman AM. Surgery and Chronic Pancreatitis. Surgical
Clinic of North America April 2001; 81: 431-55.
4. Sidhu SS, Tandon RK. The Pathogenesis of Chronic
Pancreatitis. Postgrad Med J 1995; 71: 67-70.
5. Sindu S, Tandon RK. Chronic pancreatitis: diagnosis and
treatment. Post Grad Med J 1996; 72: 327-33.
6. Toskes PP, Greenberger NJ. Acute and Chronic Pancreatitis. In:
Braunwald E, Fauci AS, Kasper LD, Hauser SL, Longo DL,
Jameson JL, editor. Principles of Internal Medicine. 15th ed.
New York: Mc Graw-Hill; 2001. p. 1792-1804.
7. Kuman RK, Sato N, Garg PK. Chronic Pancreatitis: Asia-Pasific
Consensus Report. Journal of Gastroenterology and Hepatology
2002; 17: 508-18.
8. Lin Y, Tamakoshi A, Hayakawa T, Ogawa M, Ohno Y.
Associations of Alcohol Drinking and Nutrition Intake With
Chronic Pancreatitis: Finding From a Case-Control Study in
Japan. The American Journal of Gastroenterology 2001; 96:
2622-7.
9. Hammel P, Couvelard A, O’ Toole D, Ratouis A, Sauvanet A,
Flejou JR, et al. Regression of Liver Fibrosis After Billiary
Drainage in Patients with Chronic Pancreatitis and Stenosis of
Common Bole Duct. NEJM Feb 2001; 334: 418-23.
10. Teich N, Bauer N, Mossner J, Keim V. Mutation Sceening of
Patients with Non Alcoholic Chronic Pancreatitis:
Identification of Futher Trypsinogen Variants. The American
Journal of Gastroenterology 2002; 97 : 342-6.
11. Truninger K, Malik N, Ammann RW, Muellhaupt B, Seifert B,
Muller HJ, et al. Mutations of Cystic Fibrisis Gene in Patents
with Chronic Pancreatitis. The American Journal of
Gastroenterology 2001; l96: 2658-61
12. Tandon RK. Tropical Calcific Pancreatitis. Journal of
Gastroenterology and Hepatology 1998; 13 ( suppl. ): S284-8.
13. Queneau PE, Adessi GL, Thibault P, Cleau D, Heyd B, Mantion
G, Carayon P. Early Detection  of Cancer in Patients with Chronic
Pancreatitis: Diagnostic Utility of a K-ras Point Mutation in
Pancreatic Juce. The American Journal of Gastroenterology 2001;
96: 701-4.
14. Manfredi R, Lucidi V, Gui B, Brizi MG, Vecchioli A, Maresca
G, et al. Idiopathic Chronic Pancreatitis in Children: MRCP
after Secretin Administration. Radiology  September 2002; 224
: 675-82.
15. Kasmin FE, Siegel JH. Endoscopic Therapy for Chronic
Pancreatitis. Surgical Clinic of North America April 2001;  81 :
421-30.
